Evaluation of the SERM Ormeloxifene in the Treatment of Uterine Fibroid in the Reproductive Age Group
Journal Title: Journal of Syndromes - Year 2016, Vol 3, Issue 2
Abstract
Background: The search for the ideal drug for medical treatment of fibroids is on. SERMs appear to be novel agents for hormonal manipulations. Ormeloxifene with biweekly dosing and minimum side effects needs evaluation for the above. Method: The study was a prospective clinical observation undertaken to evaluate the efficacy of ormeloxifene in uterine fibroid in reproductive age group. Forty four (44) women aged 20-50 year age group who attended the outpatient gynaecology department, diagnosed with fibroid uterus; symptomatic or asymptomatic were recruited for the study. Ormeloxifene 60 mg was given orally twice a week for 6 months. Follow up was done at monthly interval and at the end of 6 months clinically and by USG. The primary outcome measures were fibroid size, uterine size and delta size. Secondary outcomes were measurement of menstrual blood loss using the PBAC score, hemoglobin concentration and endometrial thickness. Results: No significant changes were observed in the leiomyoma, uterine and delta size. 90.9% fibroids remained unchanged at the end of 6 months. The difference in mean hemoglobin concentration, PBAC scores and endometrial thickness were statistically significant (p<0.001). Hysterectomy was required in 5(11.36%) cases. Conclusion: Ormeloxifene does not reduce fibroid size but prevents further growth of the tumour and significantly reduces menstrual blood loss in standard doses with minimum side effects for a short period of time.
Authors and Affiliations
Mandira Dasgupta
Keywords
Related Articles
- EP ID EP240032
- DOI 10.13188/2380-6036.1000011
- Views 95
- Downloads 0
RNA Dysfunction and RNA binding Proteins in the Syndrome of ALS/FTD
RNA dysfunction and abnormal intracellular aggregates comprise a key characteristic in most neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The discoveries wit...
The Time is Now: The Need for an Intensive, Appropriate Individual Intervention for Individuals with Rett Syndrome
Rett syndrome (RTT) is a complex neurological disorder caused by an affected MECP-2 gene, primarily affecting females. In 2007, a reversal of typical clinical characteristics of MECP2 mice was performed successfully. The...
Evaluation of the SERM Ormeloxifene in the Treatment of Uterine Fibroid in the Reproductive Age Group
Background: The search for the ideal drug for medical treatment of fibroids is on. SERMs appear to be novel agents for hormonal manipulations. Ormeloxifene with biweekly dosing and minimum side effects needs evaluation f...
Recurrence of Ogilvie’s Syndrome, a Rare Postoperative Complication in Second Caesarean Section
Acute colonic pseudo obstruction (ACPO), also known as Ogilvie’s syndrome is a very rare postoperative complication of Caesarean section. It has classically been reported in critically ill patients and following cardiac...
Numb Chin Syndrome with Four Fulminant Attacks in 16 Years
We present a case report of an otherwise healthy 68-year-old man with a 16-year follow-up of recurrent sudden and severe attacks of painful but benign numb chin syndrome (NCS). The patient presented with only one subject...